A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus
Arthritis Rheumatol. 2022. Epub ahead of print doi: 10.1002/art.42392
Given the chronic nature of SLE and need for treatment over a prolonged period of time, determining the long-term safety and efficacy of treatments is important. With this in mind, Kalunian, et al. explore the long-term safety and tolerability of anifrolumab 300 mg compared with placebo, over a 3-year period.